TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24158313

Group type: EXPERIMENTAL
Intervention: Early removal group (chest tube removal at drainage volume of 300 ml/24 h or less)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Traditional management group (chest tube removal when drainage volume is less than 100 ml/24 h)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Early removal group
Number of subjects: 70

Group type: COMPARATOR
Intervention: Traditional management group
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 24032186

Group type: EXPERIMENTAL
Intervention: Nape acupuncture combined with rehabilitation training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional treatment (general medication + rehabilitation training)
Number of subjects: 80
Study: 20599816

Group type: EXPERIMENTAL
Intervention: Attend-to-face condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ignore-faces condition with similar faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ignore-faces condition with dissimilar faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attend-to-face vs. ignore-faces condition
Number of subjects: 0
Study: 18699970

Group type: EXPERIMENTAL
Intervention: Presence of a preferred chewing side (PCS)
Number of subjects: 4086
Study: 15959612

Group type: EXPERIMENTAL
Intervention: Bethanechol (30 mg/day)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Cisapride (30 mg/day)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Bethanechol combined with cisapride (30 mg/day each)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 12642049

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a (10 million units/m2, daily for 7 days)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 10757556

Group type: EXPERIMENTAL
Intervention: Amifostine (1000 mg absolute)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Cisplatin/ifosfamide-based chemotherapy without amifostine (Control)
Number of subjects: 31
Study: 8955958

Group type: EXPERIMENTAL
Intervention: Immunoreactivity for NF-kappa B in glial cells of infarcted areas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunoreactivity for NF-kappa B in macrophages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunoreactivity for NF-kappa B in capillaries
Number of subjects: 0
Study: 1383970

Group type: EXPERIMENTAL
Intervention: HIGH stimulation group
Number of subjects: 37

Group type: COMPARATOR
Intervention: LOW stimulation group
Number of subjects: 37
Study: 3904977

Group type: EXPERIMENTAL
Intervention: Specific Immunotherapy Group - three monthly doses of 500 micrograms of tumor associated antigen (TAA) emulsified with complete Freund's adjuvant (CFA)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Nonspecific Immunotherapy Group - three monthly doses of CFA emulsified in saline
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control Group - no treatment postoperatively
Number of subjects: 86
Study: 30639758

Group type: EXPERIMENTAL
Intervention: Individualized, interactive intervention tailored to readiness for advanced care planning and prognostic information
Number of subjects: 460

Group type: COMPARATOR
Intervention: Symptom-management educational treatment (Control)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Individualized, interactive intervention
Number of subjects: 460
Study: 28990437

Group type: EXPERIMENTAL
Intervention: Injection volume of 2250 µL
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Injection site in thigh
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Injection speed (0-800 µL/sec)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Overall patient acceptance of injection pain
Number of subjects: 80
Study: 26873905

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 3300
Study: 25288600

Group type: EXPERIMENTAL
Intervention: Transitional Care Model (TCM) intervention delivered by a psychiatric nurse practitioner for 90 days posthospitalization
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Transitional Care Model (TCM) intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study: 22843761

Group type: EXPERIMENTAL
Intervention: Carbonated water
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cold water (4 °C)
Number of subjects: 39
Study: 20056354

Group type: EXPERIMENTAL
Intervention: 68 Gy
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: 76-78 Gy
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Bladder surface receiving >or=80 Gy
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Dose difference map in bladder neck (trigonal region)
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Baseline complaints and transurethral resection of the prostate
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Acute complaints
Number of subjects: 557
Study: 17934937

Group type: EXPERIMENTAL
Intervention: Calcipotriol/betamethasone dipropionate (Dovobet) for 4 weeks followed by calcipotriol for 8 weeks (group A)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Calcipotriol (Daivonex) alone for 12 weeks (group B)
Number of subjects: 150
Study: 16227729

Group type: EXPERIMENTAL
Intervention: Endoscopic dacryocystorhinostomy with bicanalicular silicone tube implantation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Endoscopic dacryocystorhinostomy without bicanalicular silicone tube implantation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Endoscopic dacryocystorhinostomy
Number of subjects: 24
Study: 11940375

Group type: EXPERIMENTAL
Intervention: DHEAS (100 mg q.d.) for 6 months
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study: 11107582

Group type: EXPERIMENTAL
Intervention: Purulent bacterial meningitis (PBM)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Viral meningitis (VM)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (meningeal syndrome)
Number of subjects: 38
Study: 8571309

Group type: EXPERIMENTAL
Intervention: DIC treatment
Number of subjects: 395
Study: 1748139

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (300 mg i.v.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6760679

Group type: EXPERIMENTAL
Intervention: Atenolol 50-150 mg twice daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Labetalol 200-600 mg twice daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 32
Study: 30923313

Group type: EXPERIMENTAL
Intervention: Integrated disease management (IDM)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual physician care
Number of subjects: 180
Study: 26786469

Group type: EXPERIMENTAL
Intervention: Universal preventive intervention
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Sustained attenders (SA-LI and SA-HI)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Early dropouts (EDO-LI and EDO-HI)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: EDO-HI group
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: SA-LI group
Number of subjects: 335
Study: 26675176

Group type: EXPERIMENTAL
Intervention: Web-based smoking media literacy (SML) program
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 72
Study: 24334242

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 22748976

Group type: EXPERIMENTAL
Intervention: 1.1g of n‐3 PUFA for 6 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Olive oil for 6 weeks
Number of subjects: 50
Study: 20632312

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendicectomy (LA)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Open appendicectomy (OA)
Number of subjects: 105
Study: 17373287

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 0
Study: 15542566

Group type: EXPERIMENTAL
Intervention: Isocapnic hyperventilation of frigid air (HV)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Methacholine (Meth)
Number of subjects: 10
Study: 12042891

Group type: EXPERIMENTAL
Intervention: B/HT
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 10738350

Group type: EXPERIMENTAL
Intervention: Coronary angioplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary surgery
Number of subjects: 0
Study: 7777693

Group type: EXPERIMENTAL
Intervention: Referential imagery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonreferential imagery
Number of subjects: 0
Study: 2407959

Group type: EXPERIMENTAL
Intervention: Warfarin and Aspirin (active treatment arms)
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1244
Study: 351808

Group type: EXPERIMENTAL
Intervention: Arecholine (4 milligrams)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Choline (10 grams)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scopolamine (0.5 milligram)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31415994

Group type: EXPERIMENTAL
Intervention: Svelte sirolimus‐eluting stent (SES) systems
Number of subjects: 1630

Group type: COMPARATOR
Intervention: Xience or Promus everolimus‐eluting stents (control)
Number of subjects: 1630
Study: 27171136

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 25588369

Group type: EXPERIMENTAL
Intervention: Moro juice extract (Morosil(®), 400 mg/die)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moro juice extract
Number of subjects: 0
Study: 24011656

Group type: EXPERIMENTAL
Intervention: Typical cervical manipulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham-control cervical manipulation
Number of subjects: 0
Study: 22106341

Group type: EXPERIMENTAL
Intervention: GH replacement therapy (0.24 mg/day in elderly, 0.33 mg/day in younger)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: GH replacement therapy
Number of subjects: 90
Study: 19843623

Group type: EXPERIMENTAL
Intervention: Atorvastatin (Group I) for 15 days prior to surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (Group II) with no antihyperlipidemic agents
Number of subjects: 40
Study: 17602012

Group type: EXPERIMENTAL
Intervention: Community-oriented group intervention with citizenship training and peer support combined with standard clinical treatment
Number of subjects: 114

Group type: COMPARATOR
Intervention: Standard clinical treatment with jail diversion services alone
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 114
Study: 15271972

Group type: EXPERIMENTAL
Intervention: Two-implant ball attachment group
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Single-bar group
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Triple-bar group
Number of subjects: 110
Study: 11476685

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1% plus timolol 0.5%
Number of subjects: 241

Group type: COMPARATOR
Intervention: Dorzolamide 2% plus timolol 0.5%
Number of subjects: 241
Study: 9572104

Group type: EXPERIMENTAL
Intervention: Well-being therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cognitive-behavioral treatment of residual symptoms
Number of subjects: 20
Study: 7882817

Group type: EXPERIMENTAL
Intervention: Glipizide-GITS (controlled-release glipizide)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Immediate-release glipizide
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 132
Study: 3147971

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 31486890

Group type: EXPERIMENTAL
Intervention: Amisulpride plus Olanzapine
Number of subjects: 328

Group type: COMPARATOR
Intervention: Olanzapine monotherapy (10-20 mg/day)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Amisulpride monotherapy (400-800 mg/day)
Number of subjects: 328
Study: 30027643

Group type: EXPERIMENTAL
Intervention: Anti-retroviral treatment (ART)
Number of subjects: 6
Study: 27392722

Group type: EXPERIMENTAL
Intervention: TEO First® hearing aid
Number of subjects: 31
Study: 24961363

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) targeting psycho-stimulants
Number of subjects: 126

Group type: COMPARATOR
Intervention: Non-contingent control condition
Number of subjects: 126
Study: 21735527

Group type: EXPERIMENTAL
Intervention: Provisional stenting with drug-eluting stents (DES) in group OR (stenosis < 50% of SB lumen area)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Provisional stenting with drug-eluting stents (DES) in group SR (stenosis ≥ 50% of SB lumen area)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group SR (stenosis ≥ 50% of SB lumen area)
Number of subjects: 60
Study: 20375127

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 145
Study: 18525392

Group type: EXPERIMENTAL
Intervention: Standard 3-month cardiac rehabilitation program (SCR)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Distributed cardiac rehabilitation program (DCR)
Number of subjects: 392
Study: 15878725

Group type: EXPERIMENTAL
Intervention: Medicated PD patients in a concurrent reading condition of the reproduction task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medicated PD patients in a concurrent reading condition of the production task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medicated PD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 12117445

Group type: EXPERIMENTAL
Intervention: H-FABP
Number of subjects: 41

Group type: COMPARATOR
Intervention: Myoglobin
Number of subjects: 41
Study: 10344709

Group type: EXPERIMENTAL
Intervention: Survanta
Number of subjects: 89

Group type: COMPARATOR
Intervention: Exosurf
Number of subjects: 89
Study: 8568293

Group type: EXPERIMENTAL
Intervention: 20 micrograms of vaccine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100 micrograms of vaccine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 500 micrograms of vaccine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Alum adjuvant control
Number of subjects: 30
Study: 1720370

Group type: EXPERIMENTAL
Intervention: Low-dose bleomycin (60 units)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Tetracycline (1 g)
Number of subjects: 85
Study: 6812549

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.25 micrograms/kg/min)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (no nitroglycerin)
Number of subjects: 25
Study: 31973701

Group type: EXPERIMENTAL
Intervention: Community Health Clubs (CHCs) intervention
Number of subjects: 4056
Study: 30601374

Group type: EXPERIMENTAL
Intervention: Multidose metronidazole (500 mg twice daily for 7 days)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Single-dose metronidazole (2 g single-dose)
Number of subjects: 89
Study: 29256535

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30mg daily
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600mg daily
Number of subjects: 135

Group type: COMPARATOR
Intervention: Healthy control
Number of subjects: 135
Study: 26655100

Group type: EXPERIMENTAL
Intervention: Active balance exercises (progressive, highly challenging group exercise program, twice weekly for 90 minutes)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Active balance exercises
Number of subjects: 23

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 23
Study: 25234605

Group type: EXPERIMENTAL
Intervention: Dietary treatment (D)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Combined treatment (DE)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Exercise (E)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 61
Study: 21716151

Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Passive Recovery (TPASS)
Number of subjects: 10
Study: 18982438

Group type: EXPERIMENTAL
Intervention: Single vein (SV) approach
Number of subjects: 15

Group type: COMPARATOR
Intervention: Double vein (DV) approach
Number of subjects: 15
Study: 18021120

Group type: EXPERIMENTAL
Intervention: Explaining technical terms in consent forms
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Understanding of randomized controlled trials
Number of subjects: 17
Study: 15214742

Group type: EXPERIMENTAL
Intervention: Oral indomethacin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous indomethacin
Number of subjects: 30
Study: 11210071

Group type: EXPERIMENTAL
Intervention: Bioabsorbable barrier (polyglactin 910)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Non-resorbable barrier (expanded polytetrafluoroethylene [ePTFE])
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Both groups (bioabsorbable and non-resorbable barriers)
Number of subjects: 9
Study: 9738165

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stent implantation
Number of subjects: 0
Study: 7972619

Group type: EXPERIMENTAL
Intervention: Controlled ambulatory activities (alphabetizing, editing task, brisk walk, solving word puzzles, eating lunch)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Laboratory measurements
Number of subjects: 37
Study: 2702243

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) + Salbutamol (S)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 4684623

Group type: EXPERIMENTAL
Intervention: Marijuana cigarette containing 4.8 mg Delta(9)-THC
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Marijuana cigarette containing 9.1 mg Delta(9)-THC
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Marijuana cigarette containing less than 0.01 mg Delta(9)-THC
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Low doses of marijuana
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High doses of marijuana
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Marijuana (all doses)
Number of subjects: 75
Study: 29893313

Group type: EXPERIMENTAL
Intervention: Bilateral salpingectomy (Group 1; n = 15)
Number of subjects: 62

Group type: COMPARATOR
Intervention: No bilateral salpingectomy (Group 2; n = 15)
Number of subjects: 62
Study: 27454135

Group type: EXPERIMENTAL
Intervention: Compression Garment (CG)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal Garment (CON)
Number of subjects: 18
Study: 25240806

Group type: EXPERIMENTAL
Intervention: ICD therapy for women
Number of subjects: 0
Study: 22516403

Group type: EXPERIMENTAL
Intervention: Pelvic lead shielding during radial access
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Pelvic lead shielding during femoral access
Number of subjects: 210
Study: 19935821

Group type: EXPERIMENTAL
Intervention: Dietary practice during the complementary feeding period, primarily using commercial food products.
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Breast milk or formula consumption.
Number of subjects: 286

Group type: COMPARATOR
Intervention: Commercial complementary food.
Number of subjects: 286
Study: 18219053

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 15142210

Group type: EXPERIMENTAL
Intervention: Vector-ultrasonic system (VUS)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 38
Study: 11408206

Group type: EXPERIMENTAL
Intervention: 5 microg of rhG‐CSF/kg of body weight intravenously injected
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combination of ANC and CL(CR)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CL(CR) in patients with ANC of <1,000/microl
Number of subjects: 25
Study: 9741036

Group type: EXPERIMENTAL
Intervention: Experimental group (17 subjects) - kept 2-week food diaries under the belief that the researcher was verifying their report.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (11 subjects) - asked to self-monitor for two more weeks without verification.
Number of subjects: 28
Study: 7976985

Group type: EXPERIMENTAL
Intervention: Prophylactic aspirin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine substitutes as adjunctive therapy in smoking cessation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy following myocardial infarction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory agents in the treatment of asthma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antidepressant drugs as therapy for mild depression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased fiber intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular exercise
Number of subjects: 0
Study: 2493342

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Stored samples
Number of subjects: 216
Study: 31240711

Group type: EXPERIMENTAL
Intervention: Pre-operative colloid fluid bolus of 6 ml kg-1 lean body weight
Number of subjects: 80

Group type: COMPARATOR
Intervention: No pre-operative fluid bolus
Number of subjects: 80
Study: 28321566

Group type: EXPERIMENTAL
Intervention: C2 tDCS
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: DLPFC tDCS
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 42
Study: 25374095

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Midazolam (0.045 mg/kg)
Number of subjects: 62
Study: 24011178

Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation (one home visit followed by seven weekly telephone calls)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Hospital-based pulmonary rehabilitation (twice weekly supervised exercise training and education for eight weeks)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation
Number of subjects: 166

Group type: COMPARATOR
Intervention: Hospital-based pulmonary rehabilitation
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Home-based and hospital-based pulmonary rehabilitation
Number of subjects: 166